Norway’s Algeta confirms takeover bid approach from Bayer
In response to recent media commentary, the board of directors of Norway’s Algeta (OSE: ALGETA) this morning confirmed that it has received a preliminary acquisition proposal from German pharma and chemical major Bayer (BAYN: DE).
The commentary in the media refers to an acquisition proposal at a price of 306 Norwegian kroner per Algeta share. This is incorrect, said Algeta, noting that in fact the offer price is 336 kroner per Algeta share. This would represent a total acquisition cost of around $2.4 billion, a 27% premium to the stock's last close. Algeta shares rose 30% to a record 345.10 kroner by 9:00 this morning.
Would give Bayer full ownership of Xofigo
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze